Razavi, P., An, J. A., Erazo, T., Schwartz, P., Ferrer, L., Gallinato, O., Papillon, L., Colin, T., Bossy, M., AndrE, R., Davies, J., Falato, C., Rashid, A., Sreenivasan, S., Decque, A., Remorino, A., Dellamonica, D., Menu, P. (2025). Prediction of real-world progression free survival (rwPFS) using a multimodal machine learning (ML) model for patients with HR+ HER2- metastatic breast cancer (mBC) undergoing first line (1L) treatment with cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) and endocrine therapy (ET).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.e13088